QUANTUM – DRIVEN THERANOSTICS PLATFORM
RESEARCH GRANTS
Illustration of a few projects funded by QUANTALPHA Research Grants
Due to the large number of research grant applications currently under review by our Scientific Advisory Board, no new application is possible, this until further notice.
FAP Theranostics- Cancer-Associated Fibroblasts (CAFs)-Targeted Imaging and Therapy and Combination with Immunotherapy or Chemotherapy
This project aims to utilize 177Lu and 225Ac conjugated with FAP for targeted imaging and therapy in solid tumors, focusing on cancer-associated fibroblasts (CAFs). Additionally, it seeks to investigate the synergistic effects of PD-L1 immunotherapy or chemotherapy…
Development of 18F-labeled radioligands for PET imaging of PD-L1 positive tumors
Immune checkpoint inhibitor (ICI) therapy targeting the PD-1/PD-L1 axis is a very promising treatment option for cancer therapy. However, since only ca. 30% of patients respond to ICI therapy, a diagnostic tool is highly sought after to identify those patients prior…
Investigation of 161Tb-based PSMA radioligand therapy: efficacy and safety evaluation in clinically relevant mouse models
Targeted radionuclide therapy delivers ionizing radiation to tumor cells through the accumulation of intravenously injected radiopharmaceuticals. In the case of metastatic castration-resistant prostate cancer, the currently used agent [177Lu]Lu-PSMA-617 is limited by…